Literature DB >> 17985200

Lymphatic metastasis in breast cancer: importance and new insights into cellular and molecular mechanisms.

Suzanne Eccles1, Lenaic Paon, Jonathan Sleeman.   

Abstract

Lymph node metastasis is the main prognosis factor in a number of malignancies, including breast carcinomas. The means by which lymph node metastases arise is not fully understood, and many questions remain about their importance in the further spread of breast cancer. Nevertheless, a number of key cellular and molecular mechanisms of lymphatic metastasis have been identified. These include induction of intra- or peri-tumoral lymphangiogenesis or co-option of existing lymphatic vessels to allow tumour cells to enter the lymphatics, although it remains to be established whether this is primarily an active or passive process. Gene expression microarrays and functional studies in vitro and in vivo, together with detailed clinical observations have identified a number of molecules that can play a role in the genesis of lymph node metastases. These include the well-recognised lymphangiogenic cytokines VEGF-C and VEGF-D as well as chemokine-receptor interactions, integrins and downstream signalling pathways. This paper briefly reviews current clinical and experimental evidence for the underlying mechanisms and significance of lymphatic metastasis in breast cancer and highlights questions that still need to be addressed.

Entities:  

Mesh:

Year:  2007        PMID: 17985200     DOI: 10.1007/s10585-007-9123-5

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  149 in total

1.  Correlation of hypoxia inducible factor-1alpha with lymphatic metastasis via vascular endothelial growth factor-C in human esophageal cancer.

Authors:  Miwako Katsuta; Masao Miyashita; Hiroshi Makino; Tsutomu Nomura; Seiichi Shinji; Kiyohiko Yamashita; Takashi Tajiri; Mitsuhiro Kudo; Toshiyuki Ishiwata; Zenya Naito
Journal:  Exp Mol Pathol       Date:  2005-01-07       Impact factor: 3.362

2.  Receptor tyrosine kinase EphB4 is a survival factor in breast cancer.

Authors:  S Ram Kumar; Jasbir Singh; Guangbin Xia; Valery Krasnoperov; Loubna Hassanieh; Eric J Ley; Jeffrey Scehnet; Neil G Kumar; Debra Hawes; Michael F Press; Fred A Weaver; Parkash S Gill
Journal:  Am J Pathol       Date:  2006-07       Impact factor: 4.307

3.  Vascular endothelial growth factor family members are differentially regulated by c-erbB signaling in head and neck squamous carcinoma cells.

Authors:  P O-charoenrat; P Rhys-Evans; H Modjtahedi; S A Eccles
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

4.  Accurate assessment of lymph vessel tumor emboli in invasive ductal carcinoma of the breast according to tumor areas, and their prognostic significance.

Authors:  Chisako Yamauchi; Takahiro Hasebe; Motoki Iwasaki; Shigeru Imoto; Noriaki Wada; Masashi Fukayama; Atsushi Ochiai
Journal:  Hum Pathol       Date:  2006-10-23       Impact factor: 3.466

5.  Immunoelectron microscopic characterization of human dermal lymphatic microvascular endothelial cells. Differential expression of CD31, CD34, and type IV collagen with lymphatic endothelial cells vs blood capillary endothelial cells in normal human skin, lymphangioma, and hemangioma in situ.

Authors:  B Sauter; D Foedinger; B Sterniczky; K Wolff; K Rappersberger
Journal:  J Histochem Cytochem       Date:  1998-02       Impact factor: 2.479

6.  Interleukin 7 upregulates vascular endothelial growth factor D in breast cancer cells and induces lymphangiogenesis in vivo.

Authors:  M A A Al-Rawi; G Watkins; R E Mansel; W G Jiang
Journal:  Br J Surg       Date:  2005-03       Impact factor: 6.939

7.  Lymphatic metastasis in the absence of functional intratumor lymphatics.

Authors:  Timothy P Padera; Ananth Kadambi; Emmanuelle di Tomaso; Carla Mouta Carreira; Edward B Brown; Yves Boucher; Noah C Choi; Douglas Mathisen; John Wain; Eugene J Mark; Lance L Munn; Rakesh K Jain
Journal:  Science       Date:  2002-04-25       Impact factor: 47.728

8.  Preexisting lymphatic endothelium but not endothelial progenitor cells are essential for tumor lymphangiogenesis and lymphatic metastasis.

Authors:  Yulong He; Iiro Rajantie; Maritta Ilmonen; Taija Makinen; Marika J Karkkainen; Paula Haiko; Petri Salven; Kari Alitalo
Journal:  Cancer Res       Date:  2004-06-01       Impact factor: 12.701

9.  ErbB2 overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human breast carcinoma.

Authors:  Wentao Yang; Kristine Klos; Ying Yang; Terry L Smith; Daren Shi; Dihua Yu
Journal:  Cancer       Date:  2002-06-01       Impact factor: 6.860

10.  Rapamycin, a specific inhibitor of the mammalian target of rapamycin, suppresses lymphangiogenesis and lymphatic metastasis.

Authors:  Soichi Kobayashi; Takashi Kishimoto; Shigeyuki Kamata; Masayuki Otsuka; Masaru Miyazaki; Hiroshi Ishikura
Journal:  Cancer Sci       Date:  2007-05       Impact factor: 6.716

View more
  17 in total

1.  [Detection of lymphovascular invasion in urothelial carcinoma of the bladder through D2-40 immunostaining].

Authors:  T Martini; P Ströbel; A Steidler; N Petrakopoulou; P Erben; C Bolenz
Journal:  Urologe A       Date:  2015-01       Impact factor: 0.639

2.  Differential expression of miR-139, miR-486 and miR-21 in breast cancer patients sub-classified according to lymph node status.

Authors:  Lene Rask; Eva Balslev; Rolf Søkilde; Estrid Høgdall; Henrik Flyger; Jens Eriksen; Thomas Litman
Journal:  Cell Oncol (Dordr)       Date:  2014-07-16       Impact factor: 6.730

3.  Lymphatic-targeted therapy following neoadjuvant chemotherapy: a promising strategy for lymph node-positive breast cancer treatment.

Authors:  Jianghao Chen; Qing Yao; Hui Wang; Bo Wang; Juliang Zhang; Ting Wang; Yonggang Lv; Zenghui Han; Ling Wang
Journal:  Med Oncol       Date:  2015-05-26       Impact factor: 3.064

4.  Evaluation of the potential for lymph node metastasis using CRP 1846C>T genetic polymorphism in invasive breast cancer.

Authors:  Kaori Terata; Satoru Motoyama; Shuichi Kamata; Yudai Hinai; Masatomo Miura; Yusuke Sato; Kei Yoshino; Aki Ito; Kazuhiro Imai; Hajime Saito; Yoshihiro Minamiya
Journal:  Tumour Biol       Date:  2014-03-16

5.  CRSBP-1/LYVE-1 ligands disrupt lymphatic intercellular adhesion by inducing tyrosine phosphorylation and internalization of VE-cadherin.

Authors:  Wei-Hsien Hou; I-Hua Liu; Cheng C Tsai; Frank E Johnson; Shuan Shian Huang; Jung San Huang
Journal:  J Cell Sci       Date:  2011-04-15       Impact factor: 5.285

6.  Angiogenesis-associated sequence variants relative to breast cancer recurrence and survival.

Authors:  LaCreis R Kidd; Guy N Brock; Tiva T VanCleave; Marnita L Benford; Nicole A Lavender; Traci L Kruer; James L Wittliff
Journal:  Cancer Causes Control       Date:  2010-06-23       Impact factor: 2.506

Review 7.  Metastasis suppressor genes at the interface between the environment and tumor cell growth.

Authors:  Douglas R Hurst; Danny R Welch
Journal:  Int Rev Cell Mol Biol       Date:  2011       Impact factor: 6.813

8.  Epigenetic contributions to cancer metastasis.

Authors:  David I Rodenhiser
Journal:  Clin Exp Metastasis       Date:  2008-04-02       Impact factor: 5.150

9.  Frequent genetic differences between matched primary and metastatic breast cancer provide an approach to identification of biomarkers for disease progression.

Authors:  Andrzej B Popławski; Michał Jankowski; Stephen W Erickson; Teresita Díaz de Ståhl; E Christopher Partridge; Chiquito Crasto; Jingyu Guo; John Gibson; Uwe Menzel; Carl Eg Bruder; Aneta Kaczmarczyk; Magdalena Benetkiewicz; Robin Andersson; Johanna Sandgren; Barbara Zegarska; Dariusz Bała; Ewa Srutek; David B Allison; Arkadiusz Piotrowski; Wojciech Zegarski; Jan P Dumanski
Journal:  Eur J Hum Genet       Date:  2010-01-06       Impact factor: 4.246

10.  Inhibition of cancer cell proliferation and metastasis by insulin receptor downregulation.

Authors:  H Zhang; D H Fagan; X Zeng; K T Freeman; D Sachdev; D Yee
Journal:  Oncogene       Date:  2010-02-15       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.